HEADSpAcE | Translational studies of HEAD and neck cancer in South America and Europe

Summary
Worldwide, more than 550,000 new cases of head and neck cancer (HNC) occur each year, resulting in approximately 300,000 deaths annually. It is the 6th most common cancer in both Europe and South America. A major reason for the high mortality rate for this cancer is the late stage of diagnosis for many patients. Accurate assessment of the prognosis of HNC cases also allows for appropriate treatment decisions. HEADSpAcE will bring together a consortium of 15 partners with a long and successful record of collaboration in HNC. The impact of HEADSpAcE will be to understand reasons for late diagnosis and reduce the proportion of HNC that are diagnosed at a very late stage. It will identify the most appropriate fashion for diagnosis cancer caused by human papilloma virus, and also provide genomic evidence of strong predictors of prognosis that will have the potential to improve care and reduce treatment related morbidity. We will also develop guidelines for implementation into clinical care.
Unfold all
/
Fold all
More information & hyperlinks
Web resources: https://cordis.europa.eu/project/id/825771
Start date: 01-01-2019
End date: 30-06-2024
Total budget - Public funding: 4 097 233,00 Euro - 3 153 447,00 Euro
Cordis data

Original description

Worldwide, more than 550,000 new cases of head and neck cancer (HNC) occur each year, resulting in approximately 300,000 deaths annually. It is the 6th most common cancer in both Europe and South America. A major reason for the high mortality rate for this cancer is the late stage of diagnosis for many patients. Accurate assessment of the prognosis of HNC cases also allows for appropriate treatment decisions. HEADSpAcE will bring together a consortium of 18 partners with a long and successful record of collaboration in HNC. The impact of HEADSpAcE will be to understand reasons for late diagnosis and reduce the proportion of HNC that are diagnosed at a very late stage. It will identify the most appropriate fashion for diagnosis cancer caused by human papilloma virus, and also provide genomic evidence of strong predictors of prognosis that will have the potential to improve care and reduce treatment related morbidity. We will also develop guidelines for implementation into clinical care.

Status

SIGNED

Call topic

SC1-BHC-18-2018

Update Date

26-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.3. Treating and managing disease
H2020-EU.3.1.3.0. Cross-cutting call topics
H2020-SC1-2018-Single-Stage-RTD
SC1-BHC-18-2018 Translational collaborative cancer research between Europe and the Community of Latin American and Caribbean States (CELAC)